Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
EQS-News: MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
eqs_en 
0 14.06.23
EQS-News: Evotec presents sustainability strategy: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec presents sustainability strategy
EQS-News: Evotec presents sustainability strategy
eqs_en 
0 05.06.23
EQS-News: Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
EQS-News: Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
eqs_en 
0 02.06.23
EQS-News: MorphoSys AG Reports Outcome of Annual General Meeting 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports Outcome of Annual General Meeting 2023
EQS-News: MorphoSys AG Reports Outcome of Annual General Meeting 2023
eqs_en 
0 17.05.23
EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
eqs_en 
0 12.05.23
EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
eqs_en 
0 11.05.23
EQS-News: Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
EQS-News: Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
eqs_en 
0 09.05.23
EQS-Adhoc: Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-Adhoc: Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
EQS-Adhoc: Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
eqs_en 
0 09.05.23
EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results
EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results
eqs_en 
0 03.05.23
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
eqs_en 
0 27.04.23
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
eqs_en 
0 16.04.23
EQS-News: Evotec SE provides update on cyber attack: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE provides update on cyber attack
EQS-News: Evotec SE provides update on cyber attack
eqs_en 
0 10.04.23
EQS-Adhoc: Cyber Attack on Evotec: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-Adhoc: Cyber Attack on Evotec
EQS-Adhoc: Cyber Attack on Evotec
eqs_en 
0 07.04.23
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
eqs_en 
0 04.04.23
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
eqs_en 
0 28.03.23
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
eqs_en 
0 28.03.23
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
eqs_en 
0 28.03.23
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
eqs_en 
0 24.03.23
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
eqs_en 
0 24.03.23
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
eqs_en 
0 23.03.23
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
eqs_en 
0 21.03.23
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
eqs_en 
0 16.03.23
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
eqs_en 
0 15.03.23
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
eqs_en 
0 14.03.23
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
eqs_en 
0 09.03.23